According to filings with the U.S. Securities and Exchange Commission, Endolytix Technology is raising up to $8,000,000.00 in new funding. Sources indicate that as part of senior management President, Ruoxi Hu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Endolytix Technology
Endolytix is developing a novel therapeutics to address the most resistant of antibiotic infections that are difficult to treat, and patient tolerance for current therapies are low. Endolytix Technology, Inc is developing a new therapeutic approach that addresses antibiotic resistance in nontuberculous mycobacterial infections (NTMs) such as the MAC complex and M. abscessus, as well as Mycobacterium tuberculosis. The prevalence of diagnosed NTM infections in the US alone is projected at over 150,000 cases with the incidence of new infections increasing by 8.2% annually, whereas according to the World Health Organization, 10 million people per year become ill with TB and 1.5 million die.

To learn more about Endolytix Technology, visit http://endolytix.bio/
Endolytix Technology Linkedin Page: https://www.linkedin.com/company/endolytix/

Contact:
Ruoxi Hu, President
978-223-8294

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.